Advertisement

Topics

VUMC and Bayer agree on strategic research alliance to develop new therapies for kidney diseases

02:22 EDT 12 Sep 2017 | News-Medical.net

Vanderbilt University Medical Center and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Original Article: VUMC and Bayer agree on strategic research alliance to develop new therapies for kidney diseases

NEXT ARTICLE

More From BioPortfolio on "VUMC and Bayer agree on strategic research alliance to develop new therapies for kidney diseases"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...